Skip to main content
ONCIMMUNE HOLDINGS PLC logo

ONCIMMUNE HOLDINGS PLC — Investor Relations & Filings

Ticker · ONC ISIN · GB00BYQ94H38 LEI · 213800HCYIWT6YPI1I02 IL Professional, scientific and technical activities
Open in API
Filings indexed 362 across all filing types
Latest filing 2023-07-12 Board/Management Inform…
Country GB United Kingdom
Listing IL ONC

About ONCIMMUNE HOLDINGS PLC

https://www.oncimmune.com/

Oncimmune Holdings PLC is a precision medicine and immunodiagnostics company specializing in the discovery and application of antibody and autoantibody biomarker signatures. The company's core technology is the ImmunoINSIGHTS™ platform, an advanced analytical engine for immune profiling. This platform utilizes a proprietary library of over 9,000 human antigens, bead-based multiplexed immunoassay technology, and machine learning algorithms to generate biological insights from minimal sample volumes. Oncimmune applies its expertise across therapeutic areas including immuno-oncology, autoimmune diseases, and infectious diseases. It provides biomarker discovery services, targeted panels, and advanced bioinformatics to support pharmaceutical and biotechnology partners in developing more effective and targeted treatments and diagnostics.

Recent filings

Filing Released Lang Actions
Appointment of new leadership team & board changes
Board/Management Information Classification · 98% confidence The document is an official announcement released via RNS (RNS Number : 6946F) on July 12, 2023. The content explicitly details 'Changes to the Board' and the 'Appointment of new leadership team,' including the hiring of a new CEO and Finance Director, and the stepping down of existing directors. This directly corresponds to the definition of Board/Management Information (MANG). Although it is distributed via RNS, the core subject matter is management changes, making MANG the most specific classification. The document length (7744 chars) is substantial enough to be the primary announcement, not just a brief RPA.
2023-07-12 English
Change of registered office
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number' and contains standard boilerplate language referencing RNS, the news service of the London Stock Exchange, and the Financial Conduct Authority (FCA). The content itself is a very brief announcement titled 'Change of registered office' for Oncimmune Holdings plc. Given its short length (3362 characters) and its nature as a general regulatory update that doesn't fit into specific financial reporting categories (like 10-K, ER, or DIV), it best fits the 'Regulatory Filings' category, which serves as the fallback for miscellaneous regulatory announcements. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). It is an announcement, not a detailed report, which aligns with the 'MENU VS MEAL' rule suggesting RPA or RNS. Since it is a general regulatory notification provided via the RNS system, RNS is the most appropriate classification.
2023-06-26 English
Transition of Executive Leadership
Board/Management Information Classification · 99% confidence The document is an official announcement disseminated via RNS (Regulatory News Service), indicated by the 'RNS Number' and the closing footer referencing RNS and the London Stock Exchange. The core content announces a 'Transition of Executive Leadership' including the stepping down of the CEO and the appointment of an acting CEO, along with an 'Announcement of next phase plan for growth in FY2024'. This content directly relates to changes in senior management and board composition. This aligns perfectly with the definition for Board/Management Information (MANG). Although it is distributed via RNS, the specific subject matter is management change, making MANG the most precise classification over the general RNS fallback.
2023-06-23 English
Correction to interim results
Earnings Release Classification · 99% confidence The document is a short announcement released via RNS (RNS Number: 9046C) on June 15, 2023. The core content is a 'Correction to unaudited interim results for the 12 months to 31 May 2022'. It details a specific accounting error and states that the Company 'intends to publish corrected unaudited interim results for the 12 months to 31 May 2022 in due course.' Because this document is a brief announcement about a correction to a prior report, and not the comprehensive corrected report itself, it fits the criteria for a general regulatory announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a short, specific regulatory update that isn't a standard financial report (like 10-K or IR) or a specific event announcement (like DIV or ER). It is not a Report Publication Announcement (RPA) because it is announcing a correction/re-issuance, not the publication of a standard report. H1 2022
2023-06-15 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document explicitly starts with 'RNS Number' and contains boilerplate language referencing 'RNS, the news service of the London Stock Exchange' and the 'Financial Conduct Authority'. The content details a 'TR-1: Standard form for notification of major holdings' regarding an acquisition/disposal of voting rights by a shareholder (MI Chelverton UK Equity Growth Fund). This type of mandatory disclosure regarding significant changes in share ownership thresholds is a specific regulatory filing type. While it is a regulatory filing, the presence of the RNS header and the nature of the notification strongly suggest classification as a general regulatory announcement, which aligns best with the 'Regulatory Filings' category (RNS) or potentially 'Major Shareholding Notification' (MRQ). Since TR-1 forms are standard regulatory disclosures distributed via RNS, and MRQ is defined as 'Notification of changes in significant share ownership levels (crossing thresholds)', MRQ is the most precise fit for a TR-1 major holding notification.
2023-06-13 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an official notification released via RNS (RNS Number : 6994B) on June 5, 2023. The content explicitly details a 'Director/PDMR Dealing' transaction where the Chief Executive Officer, Dr Adam Mark Hill, purchased ordinary shares. This type of filing, reporting personal share transactions by company directors and executives, directly corresponds to the definition of 'Director's Dealing'. The reference to 'Article 19 of the UK Market Abuse Regulation' further confirms its regulatory nature regarding insider transactions. Therefore, the appropriate code is DIRS.
2023-06-05 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.